Stock Watch: Novartis Earnings Get Interesting Boost
How Interest Rate Rises Help Prop Pharma Profits
A number of facets from last quarter’s earnings season carried over to Novartis’s first-quarter report, including pipeline attrition and the dependence of sales growth on a single product. While new, still minor products are hoped eventually to buffer its patent expiries, help from another corner has emerged.
